Corticosteroid implants for chronic non-infectious uveitis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Brady, Christopher J ^a   Villanti, Andrea C ^b   Law, Hua Andrew ^b   Rahimy, Ehsan ^c   Reddy, Rahul ^d   Sieving, Pamela C ^e   Garg, Sunir J ^c   Tang, Johnny ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Associated Retinal Consultants   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; DRUG IMPLANT; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

CATARACTOGENESIS; DRUG EFFICACY; DRUG SAFETY; EMBASE; ENDOPHTHALMITIS; HUMAN; IMMUNOMODULATION; INFORMATION RETRIEVAL; INTERMEDIATE UVEITIS; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA TEAR; REVIEW; SYSTEMATIC REVIEW; UVEITIS; ADULT; CHRONIC DISEASE; DRUG IMPLANT; HEALTH CARE QUALITY; RECURRENT DISEASE;

ADRENAL CORTEX HORMONES; ADULT; CHRONIC DISEASE; DRUG IMPLANTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STANDARD OF CARE; UVEITIS;

EID: 84969523002     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010469.pub2     Document Type: Review

References (79)

1. Frick KD, Drye LT, Kempen JH, Dunn JP, Holland GN, Latkany P, et al. Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial. Investigative Ophthalmology and Visual Science 2012;53(3):1169-76.
2. Friedman DS, Holbrook JT, Ansari H, Alexander J, Burke A, Reed SB, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology 2013;120(8):1571-9.
3. Holbrook JT, Kempen JH, Prusakowski NA, Altaweel MM, Jabs DA. Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial - lessons for comparative effectiveness trials. Clinical Trials 2011;8(6):736-43.
4. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011;118(10):1916-26.
5. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. American Journal of Ophthalmology 2010;149(4):550-61.
6. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, et al. Erratum: Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: The Multicenter Uveitis Steroid Treatment Trial (Ophthalmology (2011) 118 (1916-26)). Ophthalmology 2012;119(2):212.
7. Multicenter Uveitis Steroid Treatment Trial Follow-up Study Research Group. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study. Ophthalmology 2015;122(10):1976-86.
8. Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE, et al. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. Ophthalmology 2014;121(10):1855-62.
9. Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland G, Rao NA, et al. Outcome of treatment of uveitic macular edema: the Multicenter Uveitis Steroid Treatment Trial 2-year results. Ophthalmology 2015;122(11):2351-9.
10. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010; Vol. 117, issue 3:567-75.
11. Pavesio CE, Bairi K. Evaluation of an intravitreal fluocinolone acetonide implant vs. standard systemic therapy in noninfectious posterior uveitis. American Academy of Ophthalmology. 2006:194.
12. Acharya N, Young L. Sustained-release drug implants for the treatment of intraocular disease. International Ophthalmology Clinics 2004;44(3):33-9.
13. Anonymous . Good results from eye implant study. Treatment Review 1995, (16):4.
14. Ansari H, Kempen JH. Proof of concept for combined insertion of fluocinolone acetonide and glaucoma drainage implants for eyes with uveitis and glaucoma. American Journal of Ophthalmology 2010;149(5):699-700.
15. Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. Journal of Ocular Pharmacology and Therapeutics 2013;29(5):501-7.
16. Bollinger KE, Smith SD. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Current Opinion in Ophthalmology 2009;20(2):99-103.
17. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Archives of Ophthalmology 2008;126(9):1191-201.
18. Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology 2013;120(3):583-7.
19. Cano-Parra J, Diaz-Llopis M. New drugs in the treatment of noninfectious uveitis. Archivos de la Sociedad Espanola de Oftalmologia 2006;81(12):671-3.
20. CTRI/2014/12/004726 . To assess the safety & efficacy of fluocinolone acetonide intravitreal (FAI) insert in patients with chronic, non-infectious uveitis affecting the posterior segment of the eye. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8285 accessed 15 January 2016.
21. CTRI/2014/07/005337 . A research to study the effect of fluocinolone Aaetonide intravitreal (FAI) insert in patients with inflammation of middle layer of the eye. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=9684 (accessed 15 January 2016).
22. Eng K, Kertes P. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema: Commentary. Evidence-Based Ophthalmology 2007;8(3):170-2.
23. Ermakova NA. Efficacy of corticosteroids and cyclosporin in the treatment of retinal vasculitis in patients with Behcet's disease. Advances in Experimental Medicine and Biology 2003;528:563-5.
24. Galor A, Margolis R, Kaiser PK, Lowder CY. Vitreous band formation and the sustained-release, intravitreal fluocinolone (Retisert) implant. Archives of Ophthalmology 2007;125(6):836-8.
25. Garg S. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: Thirty-four-week results of a multicenter randomized clinical study. Evidence-Based Ophthalmology 2006;7(4):216-7.
26. Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Archives of Ophthalmology 2007; Vol. 125, issue 11:1478-85.
27. Ibrahim M, Nguyen QD. Treatment of posterior uveitis with a fluocinolone acetonide implant. Evidence-Based Ophthalmology 2009;10(4):224-6.
28. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; Vol. 107, issue 11:2024-33.
29. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina 2000;20:402-3.
30. Jaffe GJ, Martin D, Callanan D, Levy B. Fluocinolone acetonide intravitreal implant to treat posterior uveitis: 2-year results of a multi-center clinical trial. Investigative Ophthalmology and Visual Science 2005;46(13):ARVO E-abstract 2386.
31. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005; Vol. 112, issue 7:1192-8.
32. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; Vol. 113, issue 6:1020-7.
33. Jaffe GJ, Martin DF, Callanan D, Levy B, Comstock T. Fluocinolone acetonide intravitreal implant to treat posterior segment uveitis: 3-year results of a multi-center clinical trial. Investigative Ophthalmology and Visual Science 2006;47(13):ARVO E-abstract 1523.
34. Kim SJ. Diagnosis and management of noninfectious pediatric uveitis. International Ophthalmology Clinics 2011;51(1):129-45.
35. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Archives of Ophthalmology 2007; Vol. 125, issue 3:309-17.
36. Lightman S, Belfort Jr R, Naik RK, Lowder C, Foster CS, Rentz AM, et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Investigative Ophthalmology and Visual Science 2013;54(7):4864-70.
37. Lowder C, Belfort Jr R, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Archives of Ophthalmology 2011;129(5):545-53.
38. Mercante AR, Huang SS, Reddy R. Cystoid macular edema in non-infectious uveitis treated with fluocinolone acetonide intravitreal implant: 3-year results of a multi-center clinical trial. Investigative Ophthalmology and Visual Science 2007;48(13):ARVO E-Abstract 280.
39. Muller B, Orlic N, Pleyer U. Intravitreal fluocinolone-implant (Retisert) in posterior non-infectious uveitis - intermediate results after 34 weeks. Klinische Monatsblatter fur Augenheilkunde 2004; Vol. 221, issue Suppl 7:S8.
40. Mustakallio A, Kaufman HE, Johnston G, Wilson RS, Roberts MD, Harter JC. Corticosteroid efficacy in postoperative uveitis. Annals of Ophthalmology 1973;5(6):719-30.
41. Naik RK, Rentz AM, Foster CS, Lightman S, Belfort R, Lowder C, et al. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmology 2013;131(2):219-25.
42. NCT01694186 . Safety and efficacy of an injectable fluocinolone acetonide intravitreal insert. clinicaltrials.gov/show/NCT01694186 (accessed 15 January 2016).
43. NCT02309385 . Safety and efficacy study of DSP-visulex for the treatment of anterior uveitis. clinicaltrials.gov/show/NCT02309385 (accessed 15 January 2016).
44. NCT02482129 . Proof of concept study to evaluate safety and efficacy of LME636 in the treatment of acute anterior uveitis. clinicaltrials.gov/show/NCT02482129 (accessed 15 January 2016).
45. NCT02517619 . Safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic solution in non-infectious anterior uveitis (EGP-437-006). clinicaltrials.gov/show/NCT02517619 (accessed 15 January 2016).
46. Neger RE. The eyes have it, too. Positively Aware: the Monthly Journal of the Test Positive Aware Network 1996;7(3):10-1.
47. Novack GD. Clinical indications for ophthalmic corticosteroids. Ocular Surface 2008;6(4):199-202.
48. Ram J, Gupta A, Gupta V. Intraoperative dexamethasone implant in uveitis patients with cataract undergoing phacoemulsification. Ocular Immunology and Inflammation 2013;21(6):462-7.
49. Sangwan V S, Paul H A, Usner D W. Safety and efficacy of an intravitreal fluocinolone acetonide implant in subjects with noninfectious uveitis. American Academy of Ophthalmology. 2007:199.
50. Saraiya NV, Patel SS, Goldstein DA. A report of high intraocular pressure with the dexamethasone intravitreal implant. Archives of Ophthalmology 2011;129(12):1638-9.
51. Sheppard Jr JD, Nguyen QD, Usner DW, Comstock TL. Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant. Clinical Ophthalmology 2012;6(1):79-85.
52. Taylor SR, Tomkins-Netzer O, Joshi L, Morarji J, McLoone E, Lightman S. Dexamethasone implant in pediatric uveitis. Ophthalmology 2012;119(11):2412.
53. Viola F, Staurenghi G, Ratiglia R. Uveitis treated with fluocinolone acetonide implants. Archives of Ophthalmology 2009;127(1):115-6.
54. Wen S, Gao R, Hu Z. Comparison of Chinese traditional therapy combined with Western medicine and Western medicine alone in the treatment of uveitis. Eye Science 1991;7(4):205-8.
55. Williams G A, Kuppermann B D, Blumenkranz M S, Haller J A, Whitcup S M, Weinberg D V. Treatment of inflammatory macular edema with a dexamethasone posterior-segment drug delivery system. American Academy of Ophthalmology. 2004:87.
56. Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. American Journal of Ophthalmology 2009; Vol. 147, issue 6:1048-54.
57. Yeh S, Nussenblatt RB. Fluocinolone acetonide for the treatment of uveitis: weighing the balance between local and systemic immunosuppression. Archives of Ophthalmology 2008;126(9):1287-9.
58. Bollinger K, Kim J, Lowder CY, Kaiser PK, Smith SD. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology 2011;118(10):1927-31.
59. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Archives of Ophthalmology 2008;126(9):1191-201.
60. Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117(7):1393-9.
61. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
62. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 2004;218(4):223-36.
63. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;4(2):130-6.
64. Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Archives of Ophthalmology 2007;125(11):1478-85.
65. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111(3):491-500.
66. Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117(6):1134-46.
67. Haupert CL, Jaffe GJ. New and emerging treatments for patients with uveitis. International Ophthalmology Clinics 2000;40(2):205-20.
68. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
69. Jager RD, Aiello LP, Patel SC, Cunningham Jr ET. Risks of intravitreous injection: a comprehensive review. Retina 2004;24(5):676-98.
70. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment trial. Ophthalmology 2011;118(10):1916-26.
71. Lowder C, Belfort Jr R, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Archives of Ophthalmology 2011;129(5):545-53.
72. Mohammad DA, Sweet BV, Elner SG. Retisert: is the new advance in treatment of uveitis a good one?. Annals of Pharmacotherapy 2007;41(3):449-54.
73. Nussenblatt RB. The natural history of uveitis. International Ophthalmology 1990;14(5-6):303-8.
74. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW, Fluocinolone Acetonide Study Group. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010;117(3):567-75.
75. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
76. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
77. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. British Journal of Ophthalmology 1996;80(9):844-8.
78. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010;224(Suppl 1):46-53.
79. Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. American Journal of Ophthalmology 2009;147(6):1048-54.